Altimmune (ALT) Other Operating Expenses (2010 - 2023)

Altimmune (ALT) posted quarterly Other Operating Expenses of $12.4 million for Q4 2023, up 276.33% quarter-over-quarter from $3.3 million in Q4 2021.

Analysis

Altimmune (ALT) Other Operating Expenses (2010 - 2023) Analysis & Trends

Altimmune (ALT) has reported Other Operating Expenses for 12 consecutive years, with $12.4 million the latest figure, recorded in Q4 2023.

In Q4 2023, Other Operating Expenses changed N/A year-over-year to $12.4 million; the TTM figure through Sep 2024 stood at $12.4 million (changed N/A YoY), while the FY2023 annual figure was $12.4 million, changed N/A from the prior year.
Other Operating Expenses rose to $12.4 million in Q4 2023 per ALT's latest filing, from $3.3 million in the prior quarter.
Across five years, Other Operating Expenses topped out at $12.4 million in Q4 2023 and bottomed at $1.0 million in Q3 2019.
Historically, Other Operating Expenses has averaged $6.2 million across 3 years, with a median of $5.7 million in 2021.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.78 Bn	130.92 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.50 Bn	77.51 Bn	3.93 Bn
3	Argenx Se	63.51 Bn	58.32 Bn	1.37 Bn
4	Moderna	58.06 Bn	52.92 Bn	52.00 Mn
5	Revolution Medicines	44.04 Bn	44.04 Bn	-
6	BeOne Medicines	40.04 Bn	34.94 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.45 Bn	32.14 Bn	992.69 Mn
8	Royalty Pharma	28.41 Bn	27.57 Bn	-
9	Insmed	27.42 Bn	26.26 Bn	358.27 Mn
10	Altimmune	625.13 Mn	625.13 Mn	-

Historic Data

Download Data